Abstract
It has been over 50 years since the discovery of interferon. While initially touted as “the wonder drug” for cancer therapy, the reality of interferon use as a treatment for cancer has been far different. Today, interferon is used predominantly as adjuvant therapy in renal cell carcinoma and melanoma and is being evaluated for potential new applications in other malignancies, including leukemias, lymphomas, ovarian and prostate cancer, and tumors of the central nervous system. In this review we will discuss the outcome and challenges of interferon administration in malignancies and the future of this first “cytokine” in cancer therapy.
Keywords: Interferon, PEG-Intron, cytokine, cancer, malignancy, tumor, anti-tumor drugs
Current Drug Therapy
Title: Interferon Therapy for Malignant Solid Tumors
Volume: 5 Issue: 2
Author(s): Katherine E. Warren and Howard A. Young
Affiliation:
Keywords: Interferon, PEG-Intron, cytokine, cancer, malignancy, tumor, anti-tumor drugs
Abstract: It has been over 50 years since the discovery of interferon. While initially touted as “the wonder drug” for cancer therapy, the reality of interferon use as a treatment for cancer has been far different. Today, interferon is used predominantly as adjuvant therapy in renal cell carcinoma and melanoma and is being evaluated for potential new applications in other malignancies, including leukemias, lymphomas, ovarian and prostate cancer, and tumors of the central nervous system. In this review we will discuss the outcome and challenges of interferon administration in malignancies and the future of this first “cytokine” in cancer therapy.
Export Options
About this article
Cite this article as:
E. Warren Katherine and A. Young Howard, Interferon Therapy for Malignant Solid Tumors, Current Drug Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157488510791065058
DOI https://dx.doi.org/10.2174/157488510791065058 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment Directed to Signalling Molecules in Patients with Advanced Differentiated Thyroid Cancer
Anti-Cancer Agents in Medicinal Chemistry Adrenomedullin-RAMP2 System in Cardiovascular Development and Homeostasis
Current Hypertension Reviews Prostate Cancer Immunotherapy: An Evolving Field
Current Cancer Therapy Reviews Gene Therapy for Lysosomal Storage Diseases: Progress, Challenges and Future Prospects
Current Pharmaceutical Design The Vitamin D/CYP24A1 Story in Cancer
Anti-Cancer Agents in Medicinal Chemistry Multiple Functions of Mammalian Germinal Center Kinases
Current Chemical Biology Free Radicals in Diseases and Potential Role of Phytoconstituents-A Cause with Emerging Importance
Current Chemical Biology MicroRNAs in Esophageal Adenocarcinoma: Functional Significance and Potential for the Development of New Molecular Disease Markers
Current Pharmaceutical Design Tumour Targeting with Systemically Administered Bacteria
Current Gene Therapy New Chemotherapy and Immunotherapy for Tuberculosis
Current Respiratory Medicine Reviews Inherited Copper Transport Disorders: Biochemical Mechanisms, Diagnosis, and Treatment
Current Drug Metabolism Voltage-Dependent Potassium Channels Kv1.3 and Kv1.5 in Human Cancer
Current Cancer Drug Targets Insight View on Synthetic Strategies and Biological Applications of Pyrimidobenzothiazoles
Mini-Reviews in Organic Chemistry HIF Prolyl-4-hydroxylase Interacting Proteins: Consequences for Drug Targeting
Current Pharmaceutical Design Editorial (Thematic Issue: Antiangiogenic Agents in the Management of Solid Malignancies)
Current Angiogenesis (Discontinued) Emerging Immunotargets in Metastatic Renal Cell Carcinoma
Current Drug Targets Dendrimers in Cancer Therapeutics and Diagnosis
Current Drug Metabolism V-ATPase Subunit Interactions: The Long Road to Therapeutic Targeting
Current Protein & Peptide Science Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis
Current Pharmaceutical Design PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology